FDA Clears Philips AI-guided Imaging Solution for Minimally Invasive Mitral Valve Repair

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Philips for EchoNavigator R5.0 with DeviceGuide, an artificial intelligence-based software designed to support physicians during minimally invasive mitral valve repair procedures. The solution provides real-time visualization and guidance in one of interventional cardiology’s more technically demanding interventions.
DeviceGuide was developed in collaboration with Edwards Lifesciences, combining Philips’ imaging and AI capabilities with Edwards’ expertise in structural heart therapies. The software is designed to improve workflow during mitral transcatheter edge-to-edge repair (M-TEER), a minimally invasive alternative to open-heart surgery for patients with mitral regurgitation.
Built on Philips’ echo-fluoro fusion technology, the system integrates live ultrasound and X-ray imaging into a unified view. Its AI algorithm automatically tracks and visualizes the repair device in real time, helping clinicians navigate and position it more precisely. “The AI software serves as an assistive tool; the physician always remains in control. This isn’t about replacing expertise – it’s about amplifying it,” said Dr. Atul Gupta, Chief Medical Officer Diagnosis & Treatment at Philips.
In developing DeviceGuide, Philips and Edwards worked closely with investigational sites in Europe and the U.S., including a team at the Structural Heart and Valve Center at NewYork-Presbyterian/Columbia University Irving Medical Center, led by interventional cardiologist Susheel Kumar Kodali, MD, director, and Rebecca T. Hahn, MD, director of interventional echocardiography. “Since AI auto-aligns imaging to the device in real time and continuously informs the interventionalist about the location of the device in space on the imaging screen, it minimizes unnecessary repositioning of the imaging window, streamlines procedural guidance, and may improve the precision of device implantation,” said Dr. Rebecca T. Hahn.
The solution integrates with Philips’ Azurion image-guided therapy platform and forms part of its broader connected cardiology portfolio. The company positions DeviceGuide as a step toward more AI-enabled catheterization labs, where imaging, devices, and real-time data are combined to support more consistent and efficient minimally invasive procedures.
